Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade.

Authors:
Sun B; Xun Z; Zhang N; Liu K; Chen X and 1 more

Journal:
Cancer Cell Int

Publication Year: 2023

DOI:
10.1186/s12935-023-03158-4

PMCID:
PMC10704754

PMID:
38066642

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Cancer Cell Int

Abbreviation: Cancer Cell Int

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
AAA237, an SKP2 inhibitor, suppresses glioblastoma by inducing BNIP3-dependent autophagy through th…
Zhang Y; Li W; Yang Y and 8 more (2024) - Transparency Score: 3/6
Abnormal arginine synthesis confers worse prognosis in patients with middle third gastric cancer.
Hong L; Tang X; Han J and 3 more (2024) - Transparency Score: 3/6
ACADL-YAP axis activity in non-small cell lung cancer carcinogenicity.
Chen K; Hong C; Kong W and 8 more (2024) - Transparency Score: 3/6
A cuproptosis-related gene expression signature predicting clinical prognosis and immune responses …
Ren H; Liu C; Zhang C and 7 more (2024) - Transparency Score: 3/6
A cuproptosis score model and prognostic score model can evaluate clinical characteristics and immu…
Tang Y; Wang T; Li Q and 1 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding This work was supported by National High Level Hospital Clinical Research Funding (2022-PUMCH-B-128), CAMS Innovation Fund for Medical Sciences (CIFMS) (2022-I2M-C&T-A-003), CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-061, 2021-I2M-1-003), CSCO-hengrui Cancer Research Fund (Y-HR2019-0239, Y-HR2020MS-0415, Y-HR2020QN-0414), CSCO-MSD Cancer Research Fund (Y-MSDZD2021-0213) and National Ten-thousand Talent Program."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025